| Ident. | Authors (with country if any) | Title |
|---|
| 000012 |
Thomas Müller [Allemagne] ; Thomas Haas [Allemagne] ; Sven Lütge [Allemagne] ; Marion Marg [Allemagne] ; Reinhard Ehret [Allemagne] | Trichophagia Affects Response to Duodenal Levodopa/Carbidopa Gel Administration |
| 000060 |
Fabian Klostermann [Allemagne] ; Constanze Jugel [Allemagne] ; Miriam Bömelburg [Allemagne] ; Frank Marzinzik [Allemagne] ; Georg Ebersbach [Allemagne] ; Thomas Müller [Allemagne] | Severe Gastrointestinal Complications in Patients With Levodopa/Carbidopa Intestinal Gel Infusion |
| 000095 |
Antonio Cerasa [Italie] ; Pierfrancesco Pugliese [Italie] ; Demetrio Messina [Italie] ; Maurizio Morelli [Italie] ; Maria Cecilia Gioia [Italie] ; Maria Salsone [Italie] ; Fabiana Novellino [Italie] ; Giuseppe Nicoletti [Italie] ; Gennarina Arabia [Italie] ; Aldo Quattrone [Italie] | Prefrontal Alterations in Parkinson's Disease with Levodopa-Induced Dyskinesia During fMRI Motor Task |
| 000141 |
Kai Boelmans [Allemagne] ; Christian Gerloff [Allemagne] ; Alexander Munchau [Allemagne] | Long-Lasting Effect of Levodopa on Holmes' Tremor |
| 000162 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased Levels of 5-HT1A Receptor Binding in Ventral Visual Pathways in Parkinson's Disease |
| 000214 |
Michele Poletti [Italie] ; Giulio Perugi [Italie] ; Chiara Logi [Italie] ; Anna Romano [Italie] ; Paolo Del Dotto [Italie] ; Roberto Ceravolo [Italie] ; Giuseppe Rossi [Italie] ; Pasquale Pepe [Italie] ; Liliana Dell'Osso [Italie] ; Ubaldo Bonuccelli [Italie] | Dopamine Agonists and Delusional Jealousy in Parkinson's Disease: A Cross-Sectional Prevalence Study |
| 000280 |
Lissa S. Brod [États-Unis] ; Jason L. Aldred [États-Unis] ; John G. Nutt [États-Unis] | Are High Doses of Carbidopa a Concern? A Randomized, Clinical Trial in Parkinson's Disease |
| 000287 |
Paul B. Tawadros [Australie] ; Dennis Cordato [Australie] ; Ian Cathers [Australie] ; John A. Burne [Australie] | An Electromyographic Study of Parkinsonian Swallowing and Its Response to Levodopa |
| 000310 |
Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; QIN LI [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France] | A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale |
| 000343 |
Anne Marthe Meppelink [Pays-Bas] ; Rickard Nyman [Suède] ; Teus Van Laar [Pays-Bas] ; Martje Drent [Pays-Bas] ; Ted Prins [Pays-Bas] ; Klaus Leonhard Leenders [Pays-Bas] | Transcutaneous Port for Continuous Duodenal Levodopa/ Carbidopa Administration in Parkinson's Disease |
| 000349 |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The Selective Mu-Opioid Receptor Antagonist ADL5510 Reduces Levodopa-Induced Dyskinesia Without Affecting Antiparkinsonian Action in MPTP-Lesioned Macaque Model of Parkinson's Disease |
| 000362 |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's Disease |
| 000402 |
Diego Santos-Garcia [Espagne] ; Mercedes Macias [Espagne] ; Miguel Llaneza [Espagne] ; M Nica Grande [Espagne] ; Raúl De La Fuente-Fernandez [Canada] | Serum Vitamin B12 and Folate Levels in Parkinson's Disease Patients Treated with Duodenal Levodopa Infusion |
| 000448 |
Jasmine C. Menant [Australie] ; Mark D. Latt [Australie] ; Hylton B. Menz [Australie] ; Victor S. Fung [Australie] ; Stephen R. Lord [Australie] | Postural Sway Approaches Center of Mass Stability Limits in Parkinson's Disease |
| 000484 |
Arianna Guidubaldi [Italie] ; Carla Piano [Italie] ; Filippo M. Santorelli [Italie] ; Gabriella Silvestri [Italie] ; Martina Petracca [Italie] ; Alessandra Tessa [Italie] ; Anna Rita Bentivoglio [Italie] | Novel Mutations in SPG11 Cause Hereditary Spastic Paraplegia Associated with Early-Onset Levodopa-Responsive Parkinsonism |
| 000512 |
Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's Disease Therapeutics |
| 000524 |
Rebecca Stowe [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Kelly Handley [Royaume-Uni] ; Alexandra Furmston [Royaume-Uni] ; Katherine Deane [Royaume-Uni] ; J. J. Van Hilten [Pays-Bas] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni] | Meta-Analysis of the Comparative Efficacy and Safety of Adjuvant Treatment to Levodopa in Later Parkinson's Disease |
| 000541 |
Mathias Toft [Norvège] ; Espen Dietrichs [Norvège] | Levodopa-Responsive Parkinsonism in Probable Extrapontine Myelinolysis of the Mesencephalon |
| 000542 |
Jasper E. Visser [Pays-Bas] ; David J. Schretlen [États-Unis] ; Bastiaan R. Bloem [Pays-Bas] ; Hyder A. Jinnah [États-Unis] | Levodopa is Not a Useful Treatment for Lesch-Nyhan Disease |
| 000544 |
P. Stathis [Grèce] ; S. Konitsiotis [Grèce] ; G. Tagaris [Grèce] ; D. Peterson [Finlande] | Levetiracetam for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease |
| 000551 |
Fabian Klostermann [Allemagne] ; Constanze Jugel [Allemagne] ; Frank Marzinzik [Allemagne] | Jejunal Levodopa Infusion in Long-Term DBS Patients with Parkinson's Disease |
| 000560 |
Sabine Skodda [Allemagne] ; Andrea Flasskamp [Allemagne] ; Uwe Schlegel [Allemagne] | Instability of Syllable Repetition in Parkinson's Disease-influence of Levodopa and Deep Brain Stimulation |
| 000564 |
Antonio Cerasa [Italie] ; Demetrio Messina [Italie] ; Pierfrancesco Pugliese [Italie] ; Maurizio Morelli [Italie] ; Pierluigi Lanza [Italie] ; Maria Salsone [Italie] ; Fabiana Novellino [Italie] ; Giuseppe Nicoletti [Italie] ; Gennarina Arabia [Italie] ; Aldo Quattrone [Italie] | Increased Prefrontal Volume in PD with Levodopa-Induced Dyskinesias: A Voxel-Based Morphometry Study |
| 000617 |
Giovanni Albani [Italie] ; Nadia El Assawy [Italie] ; Stefania Cattaldo [Italie] ; Marilena De Gennaro [Italie] ; Francesca Gregorini [Italie] ; Luca Pradotto [Italie] ; Alessandro Mauro [Italie] | Electrogastrographyc Activity in Parkinson's Disease Patients With and Without Motor Fluctuations |
| 000625 |
Masahiko Kishi [Japon] ; Ryuji Sakakibara [Japon] ; Hitoshi Terada [Japon] ; Emina Ogawa [Japon] ; Fuyuki Tateno [Japon] | Does Levodopa Affect Metaiodobenzylguanidine Myocardial Accumulation in Parkinson's Disease? |
| 000645 |
Helen Ling [Royaume-Uni] ; Mark Braschinsky [Estonie] ; Pille Taba [Estonie] ; Siiri-Merike Luus [Estonie] ; Karen Doherty [Royaume-Uni] ; Anna Hotter [Autriche] ; Werner Poewe [Autriche] ; Andrew Lees (neurologue) [Royaume-Uni] | Decades of Delayed Diagnosis in 4 Levodopa-Responsive Young-Onset Monogenetic Parkinsonism Patients |
| 000648 |
Thomas Müller [Allemagne] ; Siegfried Muhlack [Allemagne] | Cysteinyl-Glycine Reduction as Marker for Levodopa-Induced Oxidative Stress in Parkinson's Disease Patients |
| 000649 |
Robert A. Hauser [États-Unis] ; Aaron L. Ellenbogen [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Ann Hsu [États-Unis] ; Martin J. O'Connell [États-Unis] ; Nishit B. Modi [États-Unis] ; Hsuan-Ming Yao [États-Unis] ; Sherron H. Kell [États-Unis] ; Suneel K. Gupta [États-Unis] | Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease |
| 000657 |
Aristide Merola [Italie] ; Maurizio Zibetti [Italie] ; Serena Angrisano [Italie] ; Laura Rizzi [Italie] ; Michele Lanotte [Italie] ; Leonardo Lopiano [Italie] | Comparison of Subthalamic Nucleus Deep Brain Stimulation and Duodopa in the Treatment of Advanced Parkinson's Disease |
| 000689 |
Alberto J. Espay [États-Unis] ; Jennifer E. Vaughan [États-Unis] ; Rakesh Shukla [États-Unis] ; Maureen Gartner [États-Unis] ; Alok Sahay [États-Unis] ; Fredy J. Revilla [États-Unis] ; Fredy J. Revilla [États-Unis] ; Andrew P. Duker [États-Unis] | Botulinum Toxin Type A for Levodopa-Induced Cervical Dyskinesias in Parkinson's Disease: Unfavorable Risk-Benefit Ratio |
| 000729 |
Daniela Berg [Allemagne] ; Jana Godau [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Karla Eggert [Allemagne] ; Ilona Csoti [Allemagne] ; Alexander Storch [Allemagne] ; Heiko Huber [Allemagne] ; Monica Morelli-Canelo [Allemagne] ; Maria Stamelou [Allemagne] ; Vincent Ries [Allemagne] ; Martin Wolz [Allemagne] ; Christine Schneider [Allemagne] ; Therese Di Paolo [Canada] ; Fabrizio Gasparini [Suisse] ; Sam Hariry [Suisse] ; Marc Vandemeulebroecke [Suisse] ; Walid Abi-Saab [Suisse] ; Katy Cooke [Royaume-Uni] ; Donald Johns [Suisse] ; Baltazar Gomez-Mancilla [Suisse] | AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials |
| 000730 |
Catherine L. Gallagher [États-Unis] ; Bradley T. Christian [États-Unis] ; James E. Holden [États-Unis] ; Onofre T. Dejesus [États-Unis] ; Robert J. Nickles [États-Unis] ; Laura Buyan-Dent [États-Unis] ; Barbara B. Bendlin [États-Unis] ; Sandra J. Harding [États-Unis] ; Charles K. Stone [États-Unis] ; Barb Mueller [États-Unis] ; Sterling C. Johnson [États-Unis] | A Within-Subject Comparison of 6-[18F]Fluoro-m-tyrosine and 6-[18F]Fluoro-L-dopa in Parkinson's Disease |
| 000734 |
Kitty K. Wong [Australie] ; Jane E. Alty [Australie] ; Amanda G. Goy [Australie] ; Sanjay Raghav [Australie] ; David C. Reutens [Australie] ; Peter A. Kempster [Australie] | A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease |
| 000781 |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates |
| 000801 |
Maria Nord [Suède] ; Peter Zsigmond [Suède] ; Anita Kullman [Suède] ; Kerstin Arstrand [Suède] ; Nil Dizdar [Suède] | The Effect of Peripheral Enzyme Inhibitors on Levodopa Concentrations in Blood and CSF |
| 000815 |
Claire L. Tomlinson [Royaume-Uni] ; Rebecca Stowe [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Caroline Rick [Royaume-Uni] ; Richard Gray [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] | Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease |
| 000851 |
Manolo Carta [Suède] ; Thomas Carlsson [Suède] ; Ana Munoz [Suède] ; Deniz Kirik [Suède] ; Anders Björklund [Suède] | Role of Serotonin Neurons in the Induction of Levodopa- and Graft-Induced Dyskinesias in Parkinson's Disease |
| 000898 |
Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni] | Pramipexole Combined with Levodopa Improves Motor Function but Reduces Dyskinesia in MPTP-Treated Common Marmosets |
| 000905 |
Victoria Newsway [Royaume-Uni] ; Mark Fish [Royaume-Uni] ; Jonathan D. Rohrer [Royaume-Uni] ; Elisa Majounie [Royaume-Uni] ; Nigel Williams [Royaume-Uni] ; Melissa Hack [Royaume-Uni] ; Jason D. Warren [Royaume-Uni] ; Huw R. Morris [Royaume-Uni] | Perry Syndrome Due to the DCTN1 G71R Mutation: A Distinctive Levodopa Responsive Disorder with Behavioral Syndrome, Vertical Gaze Palsy, and Respiratory Failure |
| 000916 |
Louisa Clare Johnston [Royaume-Uni] ; Michael John Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Andrew Christopher Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni] | Pardoprunox Reverses Motor Deficits but Induces Only Mild Dyskinesia in MPTP-Treated Common Marmosets |
| 000929 |
Ray L. Watts [États-Unis] ; Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] ; Kapil Sethi [États-Unis] ; Matthew Stern [États-Unis] ; Robert A. Hauser [États-Unis] ; Warren Olanow [États-Unis] ; Alex M. Gray [États-Unis] ; Bryan Adams [États-Unis] ; Nancy L. Earl [États-Unis] | Onset of Dyskinesia with Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson's Disease |
| 000970 |
Fabrizio Stocchi [Italie] ; Mario Zappia [Italie] ; Valentina Dall'Armi [Italie] ; Jaime Kulisevsky [Espagne] ; Paolo Lamberti [Italie] ; José Angel Obeso [Espagne] | Melevodopa/Carbidopa Effervescent Formulation in the Treatment of Motor Fluctuations in Advanced Parkinson's Disease |
| 000976 |
Emanuele Cereda [Italie] ; Michela Barichella [Italie] ; Carlo Pedrolli [Italie] ; Gianni Pezzoli [Italie] | Low-Protein and Protein-Redistribution Diets for Parkinson's Disease Patients with Motor Fluctuations: A Systematic Review |
| 000982 |
Galit Kleiner-Fisman [Canada] ; Andres Lozano [Canada] ; Elena Moro [Canada] ; Yu-Yan Poon [Canada] ; Anthony E. Lang [Canada] | Long-Term Effect of Unilateral Pallidotomy on Levodopa-Induced Dyskinesia |
| 000988 |
Cleanthe Spanaki [Grèce] ; Spiros Zafeiris [Grèce] ; Andreas Plaitakis [Grèce] | Levodopa-Aggravated Lateral Flexion of the Neck and Trunk as a Delayed Phenomenon of Unilateral Pallidotomy |
| 000989 |
Adam Zaidel [Israël] ; Hagai Bergman [Israël] ; Ya'Acov Ritov [Israël] ; Zvi Israel [Israël] | Levodopa and Subthalamic Deep Brain Stimulation Responses are not Congruent |
| 000996 |
Alberto J. Espay [États-Unis] ; Dominic C. Paviour [Royaume-Uni] ; John D. O'Sullivan [Australie] ; Robert E. Schmidt [États-Unis] ; Fredy J. Revilla [États-Unis] ; Leo Verhagen Metman [États-Unis] | Juvenile Levodopa-Responsive Parkinsonism with Early Orobuccolingual Dyskinesias and Cognitive Impairment |
| 000A01 |
Janne Gierthmühlen [Allemagne] ; Philipp Arning [Allemagne] ; Andreas Binder [Allemagne] ; Jan Herzog [Allemagne] ; Günther Deuschl [Allemagne] ; Gunnar Wasner [Allemagne] ; Ralf Baron [Allemagne] | Influence of Deep Brain Stimulation and Levodopa on Sensory Signs in Parkinson's Disease |
| 000A82 |
Tobias Warnecke [Allemagne] ; Stephan Oelenberg [Allemagne] ; Inga Teismann [Allemagne] ; Christina Hamacher [Allemagne] ; Hubertus Lohmann [Allemagne] ; Erich Bernd Ringelstein [Allemagne] ; Rainer Dziewas [Allemagne] | Endoscopic Characteristics and Levodopa Responsiveness of Swallowing Function in Progressive Supranuclear Palsy |
| 000A88 |
Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of Histamine H2 Receptor Antagonism on Levodopa-Induced Dyskinesia in the MPTP-Macaque Model of Parkinson's Disease |
| 000A89 |
Coro Paisan-Ruiz [Royaume-Uni] ; Rocio Guevara [Royaume-Uni] ; Monica Federoff [Royaume-Uni] ; Hasmet Hanagasi [Turquie] ; Fardaz Sina [Iran] ; Elahe Elahi [Iran] ; Susanne A. Schneider [Royaume-Uni, Allemagne] ; Petra Schwingenschuh [Allemagne] ; Nin Bajaj [Royaume-Uni] ; Murat Emre [Turquie] ; Andrew B. Singleton [États-Unis] ; John Hardy [Royaume-Uni] ; Kailash P. Bhatia [Allemagne] ; Sebastian Brandner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Henry Houlden [Royaume-Uni] | Early-Onset L-dopa-Responsive Parkinsonism with Pyramidal Signs Due to ATP13A2, PLA2G6, FBX07 and Spatacsin Mutations |
| 000A95 |
Valerio Pisani [Italie] ; Vincenzo Moschella [Italie] ; Monica Bari [Italie] ; Filomena Fezza [Italie] ; Salvatore Galati [Italie] ; Giorgio Bernardi [Italie] ; Paolo Stanzione [Italie] ; Antonio Pisani [Italie] ; Mauro Maccarrone [Italie] | Dynamic Changes of Anandamide in the Cerebrospinal Fluid of Parkinson's Disease Patients |
| 000B40 |
William G. Ondo [États-Unis] ; Lina Shinawi [États-Unis] ; Steven Moore [États-Unis] | Comparison of Orally Dissolving Carbidopa/Levodopa (Parcopa) to Conventional Oral Carbidopa/Levodopa: A Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Trial |
| 000B58 |
Yoshikuni Mizuno [Japon] ; Kazuko Hasegawa [Japon] ; Tomoyoshi Kondo [Japon] ; Sadako Kuno [Japon] ; Mitsutoshi Yamamoto [Japon] | Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study |
| 000B64 |
Suk Yun Kang [États-Unis, Corée du Sud] ; Toshiaki Wasaka [États-Unis] ; Ejaz A. Shamim [États-Unis] ; Sungyoung Auh [États-Unis] ; Yoshino Ueki [États-Unis] ; Grisel J. Lopez [États-Unis] ; Tetsuo Kida [États-Unis] ; Seung-Hyun Jin [États-Unis] ; Nguyet Dang [États-Unis] ; Mark Hallett [États-Unis] | Characteristics of the Sequence Effect in Parkinson's Disease |
| 000B76 |
Nasim R. Khadem [États-Unis] ; Melissa J. Nirenberg [États-Unis] | Carbidopa/Levodopa Pharmacy Errors in Parkinson's Disease |
| 000B77 |
Steven R. Schwid [États-Unis] ; Janice Bausch [États-Unis] ; David Oakes [États-Unis] ; Lynn Schuchter [États-Unis] ; Caroline Tanner [États-Unis] ; Misser Forrest [Danemark] ; Anthony E. Lang [États-Unis] ; Ira Shoulson [États-Unis] | Cancer Incidence in a Trial of an Antiapoptotic Agent for Parkinson's Disease |
| 000B92 |
Pershia Samadi [Canada] ; Marc Morissette [Canada] ; Daniel Levesque [Canada] ; Thérèse Di Paolo [Canada] | BDNF Levels Are Not Related with Levodopa-Induced Dyskinesias in MPTP Monkeys |
| 000C24 |
Pauline Belujon [États-Unis] ; Daniel J. Lodge [États-Unis] ; Anthony A. Grace [États-Unis] | Aberrant Striatal Plasticity is Specifically Associated With Dyskinesia Following Levodopa Treatment |
| 000D17 |
Marta San Luciano [États-Unis] ; Laurie Ozelius [États-Unis] ; Katherine Sims [États-Unis] ; Deborah Raymond [États-Unis] ; LIU LIU [États-Unis] ; Rachel Saunders-Pullman [États-Unis] | Responsiveness to Levodopa in Epsilon-Sarcoglycan Deletions |
| 000D20 |
Luigi M. Romito [Italie] ; Maria Fiorella Contarino [Italie] ; Nicola Vanacore [Italie] ; Anna Rita Bentivoglio [Italie] ; Massimo Scerrati [Italie] ; Alberto Albanese [Italie] | Replacement of Dopaminergic Medication with Subthalamic Nucleus Stimulation in Parkinson's Disease : Long-Term Observation |
| 000D21 |
Sasa R. Filipovie [Royaume-Uni] ; John C. Rothwell [Royaume-Uni] ; Bart P. Van De Warrenburg [Royaume-Uni, Pays-Bas] ; Kailash Bhatia [Royaume-Uni] | Repetitive Transcranial Magnetic Stimulation for Levodopa-Induced Dyskinesias in Parkinson's Disease |
| 000D35 |
Victor S. C. Fung [Australie] ; Lilie Herawati [Australie] ; YING WAN [États-Unis] | Quality of Life in Early Parkinson's Disease Treated with Levodopa/Carbidopa/Entacapone |
| 000D54 |
Peter A. Lewitt [États-Unis] ; Danna Jennings [États-Unis] ; Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] ; Adrian L. Rabinowicz [États-Unis] ; James Wang [États-Unis] ; Maria Guamieri [États-Unis] ; Jean P. Hubble [États-Unis] ; Harold Murck [États-Unis] | Pharmacokinetic-Pharmacodynamic Crossover Comparison of Two Levodopa Extension Strategies |
| 000D58 |
David Devos [France] | Patient Profile, Indications, Efficacy and Safety of Duodenal Levodopa Infusion in Advanced Parkinson's Disease |
| 000D69 |
Angelika Nebe [Allemagne] ; Georg Ebersbach [Allemagne] | Pain Intensity On and Off Levodopa in Patients with Parkinson's Disease |
| 000D75 |
Giovanni Fabbrini [Italie] ; Giovanni Defazio [Italie] ; Carlo Colosimo [Italie] ; Antonio Suppa [Italie] ; Maria Bloise [Italie] ; Alfredo Berardelli [Italie] | Onset and Spread of Dyskinesias and Motor Symptoms in Parkinson's Disease |
| 000D81 |
Joanne Difrancisco-Donoghue [États-Unis] ; Ahmed Elokda [États-Unis] ; Eric M. Lamberg [États-Unis] ; Nancy Bono [États-Unis] ; William G. Werner [États-Unis] | Norepinephrine and Cardiovascular Responses to Maximal Exercise in Parkinson's Disease On and Off Medication |
| 000E04 |
Sebastian Paus [Allemagne] ; Franziska Gadow [Allemagne] ; Michael Knapp [Allemagne] ; Christine Klein [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism |
| 000E15 |
Michela Barichella [Italie] ; Emanuele Cereda [Italie] ; Gianni Pezzoli [Italie] | Major Nutritional Issues in the Management of Parkinson's Disease |
| 000E19 |
Jane E. Alty [Australie] ; Benjamin G. Clissold [Australie] ; Craig D. Mccoll [Australie] ; Katrina A. Reardon [Australie] ; Mark Shiff [Australie] ; Peter A. Kempster [Australie] | Longitudinal Study of the Levodopa Motor Response in Parkinson's Disease: Relationship Between Cognitive Decline and Motor Function |
| 000E23 |
Sophie Molloy [Royaume-Uni] ; Thais Minett [Brésil] ; John T. O'Brien [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] ; David J. Burn [Royaume-Uni] | Levodopa Use and Sleep in Patients with Dementia with Lewy Bodies |
| 000E24 |
Robert A. Hauser [États-Unis] ; Peggy Auinger [États-Unis] ; David Oakes [États-Unis] | Levodopa Response in Early Parkinson's Disease |
| 000E25 |
Bettina Pollok [Allemagne] ; Houssain Makhloufi [Allemagne] ; Markus Butz [Allemagne] ; Joachim Gross [Royaume-Uni] ; Lars Timmermann [Allemagne] ; Lars Wojtecki [Allemagne] ; Alfons Schnitzler [Allemagne] | Levodopa Affects Functional Brain Networks in Parkinsonian Resting Tremor |
| 000E34 |
Holger Honig [Allemagne] ; Angelo Antonini [Italie] ; Pablo Martinez-Martin [Espagne] ; Ian Forgacs [Royaume-Uni] ; Guy C. Faye [Royaume-Uni] ; Thomas Fox [Allemagne] ; Karen Fox [Allemagne] ; Francesca Mancini [Italie] ; Margherita Canesi [Italie] ; Per Odin [Allemagne] ; K. Ray Chaudhuri [Royaume-Uni] | Intrajejunal Levodopa Infusion in Parkinson's Disease: A Pilot Multicenter Study of Effects on Nonmotor Symptoms and Quality of Life |
| 000E36 |
Jan Herzog [Allemagne] ; Bettina Möller [Allemagne] ; Karsten Witt [Allemagne] ; Marcus O. Pinsker [Allemagne] ; Günther Deuschl [Allemagne] ; Jens Volkmann [Allemagne] | Influence of Subthalamic Deep Brain Stimulation Versus Levodopa on Motor Perseverations in Parkinson's Disease |
| 000E47 |
Stefano Zoccolella [Italie] ; Claudia Dell'Aquila [Italie] ; Giovanni Abruzzese [Italie] ; Angelo Antonini [Italie] ; Ubaldo Bonuccelli [Italie] ; Margherita Canesi [Italie] ; Silvano Cristina [Italie] ; Roberta Marchese [Italie] ; Claudio Pacchetti [Italie] ; Roberto Zagaglia [Italie] ; Giancarlo Logroscino [Italie] ; Giovanni Defazio [Italie] ; Paolo Lamberti [Italie] ; Paolo Livrea [Italie] | Hyperhomocysteinemia in Levodopa-Treated Patients with Parkinson's Disease Dementia |
| 000E52 |
Thomas Müller [Allemagne] ; Wilfried Kuhn [Allemagne] | Homocysteine Levels After Acute Levodopa Intake in Patients with Parkinson's Disease |
| 000F04 |
Robert A. Hauser [États-Unis] ; Michel Panisset [Canada] ; Giovanni Abbruzzese [Italie] ; Linda Mancione [États-Unis] ; Nalina Dronamraju [États-Unis] ; Algirdas Kakarieka [Suisse] | Double-Blind Trial of Levodopa/Carbidopa/Entacapone Versus Levodopa/Carbidopa in Early Parkinson's Disease |
| 000F26 |
Thomas Müller [Allemagne] ; Wilfried Kuhn [Allemagne] | Cysteine Elevation in Levodopa-Treated Patients with Parkinson's Disease |
| 000F37 |
Tomoyuki Uchiyama [Japon] ; Ryuji Sakakibara [Japon] ; Tatsuya Yamamoto [Japon] ; Takashi Ito [Japon] ; Chiharu Yamaguchi [Japon] ; Yusuke Awa [Japon] ; Masashi Yano [Japon] ; Mitsuru Yanagisawa [Japon] ; Makoto Kobayashi [Japon] ; Yoshinori Higuchi [Japon] ; Tomohiko Ichikawa [Japon] ; Tomonori Yamanishi [Japon] ; Takamichi Hattori [Japon] ; Satoshi Kuwabara [Japon] | Comparing Bromocriptine Effects with Levodopa Effects on Bladder Function in Parkinson's Disease |
| 001006 |
Anna Brück [Finlande] ; Sargo Aalto [Finlande] ; Elina Rauhala [Finlande] ; Jörgen Bergman [Finlande] ; Reijo Marttila [Finlande] ; Juha O. Rinne [Finlande] | A Follow-Up Study on 6-[18F]Fluoro-L-dopa Uptake in Early Parkinson's Disease Shows Nonlinear Progression in the Putamen |
| 001008 |
Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis] | A Comparison of Treatment Thresholds in Two Large Parkinson's Disease Clinical Trial Cohorts |
| 001034 |
Fabrizio Stocchi [Italie] ; Michele Tagliati [États-Unis] ; C. Warren Olanow [États-Unis] | Treatment of Levodopa-Induced Motor Complications |
| 001041 |
Masaaki Hirayama [Japon] ; Tomohiko Nakamura [Japon] ; Norio Hori [Japon] ; Yasuo Koike [Japon] ; Gen Sobue [Japon] | The Video Images of Sleep Attacks in Parkinson's Disease |
| 001054 |
Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | The Nociceptin/Orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease |
| 001059 |
Stanley Fahn [États-Unis] | The History of Dopamine and Levodopa in the Treatment of Parkinson's Disease |
| 001068 |
Sebastian Paus [Allemagne] ; Anne Grünewald [Allemagne] ; Christine Klein [Allemagne] ; Michael Knapp [Allemagne] ; Alexander Zimprich [Allemagne] ; Bernd Janetzky [Allemagne] ; Jens C. Möller [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | The DRD2 TaqIA Polymorphism and Demand of Dopaminergic Medication in Parkinson's Disease |
| 001070 |
Christos Tsironis [Grèce] ; Marios Marselos [Grèce] ; Angelos Evangelou [Grèce] ; Spiridon Konitsiotis [Grèce] | The Course of Dyskinesia Induction by Different Treatment Schedules of Levodopa in Parkinsonian Rats : Is Continuous Dopaminergic Stimulation Necessary? |
| 001073 |
Anthony H. V. Schapira [Royaume-Uni] | The Clinical Relevance of Levodopa Toxicity in the Treatment of Parkinson's Disease |
| 001086 |
Robert A. Hauser [États-Unis] ; Lisa M. Shulman [États-Unis] ; Joel M. Trugman [États-Unis] ; John W. Roberts [États-Unis] ; Akihisa Mori [Japon] ; Rocco Ballerini [États-Unis] ; Neil M. Sussman [États-Unis] | Study of Istradefylline in Patients with Parkinson's Disease on Levodopa with Motor Fluctuations |
| 001110 |
Birgit Meiler [Allemagne] ; Jürgen Andrich [Allemagne] ; Thomas Müller [Allemagne] | Rapid Switch from Oral Antiparkinsonian Combination Drug Therapy to Duodenal Levodopa Infusion |
| 001125 |
Peter Jenner [Royaume-Uni] | Preventing and Controlling Dyskinesia in Parkinson's Disease : A View of Current Knowledge and Future Opportunities |
| 001138 |
Anthony A. Grace [États-Unis] | Physiology of the Normal and Dopamine-Depleted Basal Ganglia : Insights into Levodopa Pharmacotherapy |
| 001141 |
John G. Nutt [États-Unis] | Pharmacokinetics and Pharmacodynamics of Levodopa |
| 001167 |
Maryka Quik [États-Unis] ; Kathryn O'Leary [États-Unis] ; Caroline M. Tanner [États-Unis] | Nicotine and Parkinson's Disease : Implications for Therapy |
| 001168 |
Cory Toth [Canada] ; Martin Sutton Brown [Canada] ; Sarah Furtado [Canada] ; Oksana Suchowersky [Canada] ; Douglas Zochodne [Canada] | Neuropathy as a Potential Complication of Levodopa Use in Parkinson's Disease |
| 001190 |
Paolo Calabresi [Italie] ; Massimiliano Di Filippo [Italie] ; Veronica Ghiglieri [Italie] ; Barbara Picconi [Italie] | Molecular Mechanisms Underlying Levodopa-Induced Dyskinesia |
| 001197 |
Nir Giladi [Israël] | Medical Treatment of Freezing of Gait |
| 001207 |
C. Warren Olanow [États-Unis] | Levodopa/Dopamine Replacement Strategies in Parkinson's Disease-Future Directions |
| 001208 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] | Levodopa-Related Motor Complications-Phenomenology |
| 001209 |
Kapil Sethi [États-Unis] | Levodopa Unresponsive Symptoms in Parkinson Disease |
| 001210 |
Mercedes Serrano [Espagne] ; Belen Perez-Duenas [Espagne] ; Aida Ormazabal [Espagne] ; Rafael Artuch [Espagne] ; Jaume Campistol [Espagne] ; Rosa J. Torres [Espagne] ; Angels Garcia-Cazorla [Espagne] | Levodopa Therapy in a Lesch-Nyhan Disease Patient : Pathological, Biochemical, Neuroimaging, and Therapeutic Remarks |
| 001232 |
WON YONG LEE [Corée du Sud] ; WON TAE YOON [Corée du Sud] ; HEE YOUNG SHIN [Corée du Sud] ; SEONG HEE JEON [Corée du Sud] ; Poong-Lyul Rhee [Corée du Sud] | Helicobacter Pylori Infection and Motor Fluctuations in Patients with Parkinson's Disease |
| 001249 |
Aileen K. Ho [Royaume-Uni] ; John L. Bradshaw [Australie] ; Robert Iansek [Australie] | For Better or Worse : The Effect of Levodopa on Speech in Parkinson's Disease |
| 001266 |
Thomas Müller [Allemagne] ; Dirk Woitalla [Allemagne] ; Oliver Goetze [Allemagne, Suisse] ; Christoph Erdmann [Allemagne] | Entacapone Improves Absorption of a Coadministered Salt in Patients with Parkinson's Disease |
| 001273 |
Pedro J. Garcia Ruiz ; Angel Sesar Ignacio ; Begona Ares Pensado ; Alfonso Castro Garcia ; Fernando Alonso Frech ; Mercedes Alvarez Lopez ; José Arbelo Gonzalez ; Joan Baiges Octavio ; Juan Andrés Burguera Herandez ; Matilde Calopa Garriga ; Dulce Campos Blanco ; Belén Castano Garcia ; Manuel Carballo Cordero ; José Chacon Pena ; Anna Espino Ibanez ; Aranzazu Gorospe Onisalde ; Santiago Gimenez-Roldan ; Pilar Granes Ibanez ; Jorge Hernandez Vara ; Ramon Ibanez Alonso ; Félix Javier Jimenez Jimenez ; Jerzy Krupinski ; Jaime Kulisevsky Bojarsky ; Inés Legarda Ramirez ; Elena Lezcano Garcia ; Juan Carlos Martinez-Castrillo ; Dolores Mateo Gonzalez ; Francesc Miquel Rodriguez ; Pablo Mir Rivera ; Elena Munoz Fargas ; José Obeso Inchausti ; Jesus Olivares Romero ; José Olive Plana ; Pilar Otermin Vallejo ; Berta Pascual Sedano ; Victor Perez De Colosia Rama ; Isabel Perez Lopez-Fraile ; Albert Planas Cornes ; Victor Puente Periz ; Maria Cruz Rodriguez Oroz ; Dolores Sevillano Garcia ; Pilar Solis Perez ; José Suarez Munoz ; Julia Vaamonde Gamo ; Caridad Valero Merino ; Francesc Valldeoriola Serra ; José Miguel Velazquez Perez ; Rosa Yanez Bana ; Ivana Zamarbide Capdepon | Efficacy of Long-Term Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson's Disease with Motor Fluctuations : A Multicenter Study |
| 001274 |
John G. Nutt [États-Unis] ; Steven A. Gunzler [États-Unis] ; Trish Kirchhoff [États-Unis] ; Penelope Hogarth [États-Unis] ; Jerry L. Weaver [États-Unis] ; Michael Krams [États-Unis] ; Brenda Jamerson [États-Unis] ; Frank S. Menniti [États-Unis] ; Jaren W. Landen [États-Unis] | Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism |
| 001275 |
Jennifer G. Goldman [États-Unis] ; Christopher G. Goetz [États-Unis] ; Melanie Brandabur [États-Unis] ; Michelle Sanfilippo [États-Unis] ; Glenn T. Stebbins [États-Unis] | Effects of Dopaminergic Medications on Psychosis and Motor Function in Dementia with Lewy Bodies |
| 001292 |
Lars Timmermann [Allemagne] ; Martin Braun [Allemagne] ; Stefan Groiss [Allemagne] ; Lars Wojtecki [Allemagne] ; Stefan Ostrowski [Allemagne] ; Holger Krause [Allemagne] ; Bettina Pollok [Allemagne] ; Martin Südmeyer [Allemagne] ; Markus Ploner [Allemagne] ; Joachim Gross [Allemagne] ; Mohammad Maarouf [Allemagne] ; Jürgen Voges [Allemagne] ; Volker Sturm [Allemagne] ; Alfons Schnitzler [Allemagne] | Differential Effects of Levodopa and Subthalamic Nucleus Deep Brain Stimulation on Bradykinesia in Parkinson's Disease |
| 001400 |
Jan Zijlmans [Royaume-Uni, Pays-Bas] ; Andrew Evans [Royaume-Uni] ; Flavia Fontes [Royaume-Uni] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Svetoslav Gacinovic [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Durval Costa [Royaume-Uni, Portugal] | [123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease |
| 001417 |
J Rgen H. Olsen [Danemark] ; Karina Tangerud [Danemark] ; Lene Wermuth [Danemark] ; Kirsten Frederiksen [Danemark] ; S Ren Friis [Danemark] | Treatment with levodopa and risk for malignant melanoma |
| 001439 |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten-Year Follow-Up of Parkinson's Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa |
| 001443 |
Paolo Barone [Italie] ; Janice Lamb [Royaume-Uni] ; Amanda Ellis [Royaume-Uni] ; Zoe Clarke [Royaume-Uni] | Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease |
| 001454 |
Wolfgang H. Oertel [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Marco Zucconi [Italie] ; Heike Benes [Allemagne] ; Diego Garcia Borreguero [Espagne] ; Claudio Bassetti [Suisse] ; Markku Partinen [Finlande] ; Luigi Ferini-Strambi [Italie] ; Karin Stiasny-Kolster [Allemagne] | State of the Art in Restless Legs Syndrome Therapy : Practice Recommendations for Treating Restless Legs Syndrome |
| 001478 |
Yoshikuni Mizuno [Japon] ; Takashi Abe [Japon] ; Kazuko Hasegawa [Japon] ; Sadako Kuno [Japon] ; Tomoyoshi Kondo [Japon] ; Mitsutoshi Yamamoto [Japon] ; Mitsuyoshi Nakashima [Japon] ; Ichiro Kanazawa [Japon] | Ropinirole is effective on motor function when used as an adjunct to levodopa in parkinson's disease : STRONG study |
| 001493 |
Vincent Paille [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France] | Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias |
| 001541 |
PRAMOD KUMAR PAL [Inde] ; Talakad N. Sathyaprabha [Inde] ; Prasad Tuhina [Inde] ; Kandavel Thennarasu [Inde] | Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa |
| 001580 |
Naoki Tani [Japon] ; Youichi Saitoh [Japon] ; Haruhiko Kishima [Japon] ; Satoru Oshino [Japon] ; Jun Hatazawa [Japon] ; Kazuo Hashikawa [Japon] ; Toshiki Yoshimine [Japon] | Motor cortex stimulation for levodopa-resistant akinesia : Case report |
| 001598 |
Eldad Melamed [Israël] ; Ilan Ziv [Israël] ; Ruth Djaldetti [Israël] | Management of Motor Complications in Advanced Parkinson's Disease |
| 001600 |
Radu Constantinescu [États-Unis] ; Megan Romer [États-Unis] ; Karl Kieburtz [États-Unis] | Malignant melanoma in early Parkinson's disease : The DATATOP trial |
| 001608 |
Martin Kollensperger [Autriche] ; Nadia Stefanova [Autriche] ; Markus Reindl [Autriche] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Loss of dopaminergic responsiveness in a double lesion rat model of the parkinson variant of multiple system atrophy |
| 001614 |
Anthony P. Nicholas [États-Unis] | Levodopa-induced hyperactivity in mice treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 001615 |
Giovanni Fabbrini [Italie] ; Jonathan M. Brotchie [Canada] ; Francisco Grandas [Espagne] ; Masahiro Nomoto [Japon] ; Christopher G. Goetz [États-Unis] | Levodopa-induced dyskinesias |
| 001616 |
Panida Piboolnurak [Canada, Thaïlande] ; Anthony E. Lang [Canada] ; Andres M. Lozano [Canada] ; Janis M. Miyasaki [Canada] ; Jean A. Saint-Cyr [Canada] ; Yu-Yan W. Poon [Canada] ; William D. Hutchison [Canada] ; Jonathan O. Dostrovsky [Canada] ; Elena Moro [Canada] | Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease |
| 001617 |
Robert A. Wilcox [Australie] ; Andrew Churchyard [Australie] ; Henrik H. Dahl [Australie] ; Wendy M. Hutchison [Australie] ; Denise M. Kirby [Australie] ; Dominic Thyagarajan [Australie] | Levodopa response in Parkinsonism with multiple mitochondrial DNA deletions |
| 001618 |
Cristiane Fiquene Conti [Brésil] ; Marcio Moyses De Oliveira [Brésil] ; Régis Bruni Andriolo [Brésil] ; Humberto Saconato [Brésil] ; Alvaro Nagib Atallah [Brésil] ; Juliana Spelta Valbuza [Brésil] ; Luciane Bizari Coin De Carvalho [Brésil] ; Gilmar Fernandes Do Prado [Brésil] | Levodopa for idiopathic restless legs syndrome : Evidence-based review |
| 001619 |
Radu Constantinescu [États-Unis] ; Irene Richard [États-Unis] ; Roger Kurlan [États-Unis] | Levodopa Responsiveness in Disorders with Parkinsonism : A Review of the Literature |
| 001620 |
Dariusz Koziorowski [Pologne] ; Andrzej Friedman [Pologne] | Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease |
| 001650 |
Nadia Stefanova [Autriche] ; Martin Köllensperger [Autriche] ; Monika Hainzer [Autriche] ; Angela Cenci [Suède] ; Werner Poewe [Autriche] ; Gregor Karl Wenning [Autriche] | High dose Levodopa therapy is not toxic in multiple system atrophy: Experimental evidence |
| 001677 |
Siegfried Muhlack [Allemagne] ; Jacub Welnic [Allemagne] ; Dirk Woitalla [Allemagne] ; Thomas Müller [Allemagne] | Exercise improves efficacy of levodopa in patients with Parkinson's disease |
| 001702 |
Angelo Antonini [Italie] ; Ioannis U. Isaias [Italie] ; Margherita Canesi [Italie] ; Maurizio Zibetti [Italie] ; Francesca Mancini [Italie] ; Luigi Manfredi [Italie] ; Marco Dal Fante [Italie] ; Leonardo Lopiano [Italie] ; Gianni Pezzoli [Italie] | Duodenal levodopa infusion for advanced Parkinson's disease : 12-month treatment outcome |
| 001706 |
Astrid Thomas [Italie] ; Laura Bonanni [Italie] ; Angelo Antonini [Italie] ; Paolo Barone [Italie] ; Marco Onofrj [Italie] | Dopa-responsive pseudo-orthostatic tremor in parkinsonism |
| 001732 |
John G. Nutt [États-Unis] | Continuous dopaminergic stimulation : Is it the answer to the motor complications of Levodopa? |
| 001762 |
David B. Fitzgerald [États-Unis] ; Valeria Drago [États-Unis] ; Dean Sutherland [États-Unis] ; Kenneth M. Heilman [États-Unis] | Carbidopa/levodopa-responsive myoclonus |
| 001763 |
Claudia Trenkwalder [Allemagne] ; Heike Benes [Allemagne] ; Ludger Grote [Suède] ; Svenja Happe [Allemagne] ; Birgit Högl [Autriche] ; Johannes Mathis [Suisse] ; Gerda M. Saletu-Zyhlarz [Autriche] ; Ralf Kohnen [Allemagne] | Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome : Results from a multicenter, randomized, active controlled trial |
| 001806 |
Jaime Kulisevsky [Espagne] ; Berta Pascual-Sedano [Espagne] ; Manel Barbanoj [Espagne] ; Alexandre Gironell [Espagne] ; Javier Pagonabarraga [Espagne] ; Carmen Garcia-Sanchez [Espagne] | Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease : A double-blind study |
| 001849 |
Karin Stiasny-Kolster [Allemagne] ; Ralf Kohnen [Allemagne] ; Jens Carsten Moller [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Validation of the "L-DOPA test" for diagnosis of restless legs syndrome |
| 001852 |
Mette Brandt-Christensen [Danemark] ; Kajsa Kvist [Danemark] ; Flemming M Rkeberg Nilsson [Danemark] ; Per Kragh Andersen [Danemark] ; Lars Vedel Kessing [Danemark] | Use of antiparkinsonian drugs in Denmark : Results from a nationwide pharmacoepidemiological study |
| 001863 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies : Keys to success and roads to failure |
| 001869 |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease |
| 001881 |
Vicky L. Marshall [Royaume-Uni] ; Jim Patterson [Royaume-Uni] ; Donald M. Hadley [Royaume-Uni] ; Katherine A. Grosset [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Successful antiparkinsonian medication withdrawal in patients with parkinsonism and normal FP-CIT SPECT |
| 001889 |
Anna Brück [Finlande] ; Sargo Aalto [Finlande] ; Elina Nurmi [Finlande] ; Tero Vahlberg [Finlande] ; Jorgen Bergman [Finlande] ; Juha O. Rinne [Finlande] | Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease : A two-year follow-up study |
| 001901 |
Michela Barichella [Italie] ; Agnieszka Marczewska [Italie] ; Roberta De Notaris [Italie] ; Antonella Vairo [Italie] ; Cinzia Baldo [Italie] ; Andrea Mauri [Italie] ; Chiara Savardi [Italie] ; Gianni Pezzoli [Italie] | Special low-protein foods ameliorate postprandial off in patients with advanced Parkinson's disease |
| 001903 |
Juan Carlos Gomez-Esteban [Espagne] ; Juan Jose Zarranz ; Elena Lezcano ; Fernando Velasco ; Roberto Ciordia ; Idoia Rouco ; Jose Losada ; Iker Bilbao | Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease |
| 001930 |
Omar R. Tumilasci [Argentine] ; Juan E. Belforte [Argentine] ; Federico E. Micheli [Argentine] ; Eduardo E. Benarroch [États-Unis] ; Jorge H. Pazo [Argentine] | Quantitative study of salivary secretion in Parkinson's disease |
| 001940 |
Agnieszka Marczewska [Italie] ; Roberta De Notaris [Italie] ; Sabina Sieri [Italie] ; Michela Barichella [Italie] ; Elisabetta Fusconi [Italie] ; Gianni Pezzoli [Italie] | Protein intake in parkinsonian patients using the EPIC food frequency questionnaire |
| 001946 |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in Parkinsonian monkeys : Implication of preproenkephalin |
| 001961 |
Roberto Vetrugno [Italie] ; Manuela Contin [Italie] ; Agostino Baruzzi [Italie] ; Federica Provini [Italie] ; Giuseppe Plazzi [Italie] ; Pasquale Montagna [Italie] | Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome |
| 001967 |
Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lledo [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne] | Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study |
| 001A25 |
Benjamin G. Clissold [Australie] ; Craig D. Mccoll [Australie] ; Katrina R. Reardon [Australie] ; Mark Shiff [Australie] ; Peter A. Kempster [Australie] | Longitudinal study of the motor response to levodopa in Parkinson's disease |
| 001A30 |
MI JUNG KIM [Corée du Sud] ; Sun J. Chung [Corée du Sud] ; Young H. Sung [Corée du Sud] ; Myoung C. Lee [Corée du Sud] ; Joo-Hyuk Im [Corée du Sud] | Levodopa-responsive parkinsonism associated with hydrocephalus |
| 001A31 |
Klaus Seppi [Autriche] ; Birgit Högl [Autriche] ; Anja Diem [Autriche] ; Cecilia Peralta [Autriche] ; Gregor K. Wenning [Autriche] ; Werner Poewe [Autriche] | Levodopa-induced sleepiness in the parkinson variant of multiple system atrophy |
| 001A32 |
Davina J. Hensman [Royaume-Uni] ; Peter G. Bain [Royaume-Uni] | Levodopa can worsen tremor associated with dystonia |
| 001A51 |
Thomas Müller [Allemagne] ; Christoph Erdmann [Allemagne] ; Siegfried Muhlack [Allemagne] ; Dirk Bremen [Allemagne] ; Horst Przuntek [Allemagne] ; Dirk Woitalla [Allemagne] | Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels |
| 001A72 |
Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease |
| 001A75 |
Federico Micheli [Argentine] ; Maria Graciela Cersosimo [Argentine] ; Carlos Zuniga Ramirez [Argentine] | Hereditary spastic paraplegia associated with dopa-responsive Parkinsonism |
| 001A81 |
William Bara-Jimenez [États-Unis] ; Tzvetelina D. Dimitrova [États-Unis] ; Abdullah Sherzai [États-Unis] ; Murat Aksu [États-Unis] ; Thomas N. Chase [États-Unis] | Glutamate release inhibition ineffective in levodopa-induced motor complications |
| 001A86 |
Judith A. Strong [États-Unis] ; Arif Dalvi [États-Unis] ; Fredy J. Revilla [États-Unis] ; Alok Sahay [États-Unis] ; Frederick J. Samaha [États-Unis] ; Jeffrey A. Welge [États-Unis] ; JIANHUA GONG [États-Unis] ; Maureen Gartner [États-Unis] ; XIA YUE [États-Unis] ; LEI YU [États-Unis] | Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease |
| 001B03 |
Angela Deutschl Nder [Allemagne] ; Friedrich Asmus [Allemagne] ; Elena Marelli [Allemagne] ; Thomas Klopstock [Allemagne] ; Thomas Gasser [Allemagne] ; Kai Botzel [Allemagne] | Excellent response to apomorphine in parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication |
| 001B19 |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Roshan Cools [Royaume-Uni] ; Paul Krack [France] ; Valérie Fraix [France] ; Alina Batir [France] ; Stephan Chabardes [France] ; Alim-Louis Benabid [France] ; Trevor W. Robbins [Royaume-Uni] ; Pierre Pollak [France] | Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease |
| 001B31 |
Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees (neurologue) [Royaume-Uni] | Early piribedil monotherapy of Parkinson's disease : A planned seven-month report of the REGAIN study |
| 001B50 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5-year trial of ropinirole and L-dopa |
| 001B76 |
Concepcio Marin [Espagne] ; Esther Aguilar [Espagne] ; José A. Obeso [Espagne] | Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats |
| 001C35 |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets : Mediation by D2, not D3, dopamine receptors |
| 001C87 |
Monty A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Canada] | Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease |
| 001C91 |
Meg Morris [Australie] ; Robert Iansek [Australie] ; Jennifer Mcginley [Australie] ; Thomas Matyas [Australie] ; Frances Huxham [Australie] | Three-dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder |
| 001C99 |
Mariese A. Hely [Australie] ; John G. L. Morris [Australie] ; Wayne G. J. Reid [Australie] ; Robert Trafficante [Australie] | Sydney multicenter study of Parkinson's disease : Non-L-dopa-responsive problems dominate at 15 years |
| 001D01 |
Francisca Sueli Monte [Brésil] ; Francisco Pereira Da Silva-Junior [Brésil] ; Pedro Braga-Neto [Brésil] ; Miguel Angelo Nobre E Souza [Brésil] ; Veralice Meireles Sales De Bruin [Brésil] | Swallowing abnormalities and dyskinesia in Parkinson's disease |
| 001D04 |
Antonio Pisani [Italie] ; Diego Centonze [Italie] ; Giorgio Bemardi [Italie] ; Paolo Calabresi [Italie] | Striatal synaptic plasticity : Implications for motor learning and Parkinson's disease |
| 001D23 |
Katherine L. Widnell [États-Unis] ; Cynthia Comella [États-Unis] | Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations |
| 001D45 |
Francesca Romana Pezzella [Italie] ; Carlo Colosimo [Italie] ; Nicola Vanacore [Italie] ; Simone Di Rezze [Italie] ; Melania Chianese [Italie] ; Giovanni Fabbrini [Italie] ; Giuseppe Meco [Italie] | Prevalence and clinical features of Hedonistic homeostatic dysregulation in Parkinson's disease |
| 001D54 |
Katherine Widnell [États-Unis] | Pathophysiology of motor fluctuations in Parkinson's disease |
| 001D68 |
Cheryl Waters [États-Unis] | Other pharmacological treatments for motor complications and dyskinesias |
| 001D70 |
Theresa A. Zesiewicz [États-Unis] ; Kelly L. Sullivan [États-Unis] ; John L. Maldonado [États-Unis] ; William O. Tatum [États-Unis] ; Robert A. Hauser [États-Unis] | Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease |
| 001D79 |
Jonathan M. Brotchie [Canada] | Nondopaminergic mechanisms in levodopa-induced dyskinesia |
| 001D83 |
C. Warren Olanow [États-Unis] ; Joseph Jankovic [États-Unis] | Neuroprotective therapy in Parkinson's disease and motor complications : A search for a pathogenesis-targeted, disease-modifying strategy |
| 001D92 |
Joseph Jankovic [États-Unis] | Motor fluctuations and dyskinesias in Parkinson's disease : Clinical manifestations |
| 001E06 |
Katharina Diepold [Allemagne] ; Barbara Schütz [Allemagne] ; Kevin Rostasy [Allemagne] ; Bernd Wilken [Allemagne] ; Pia Hougaard [Danemark] ; Flemming Güttler [Danemark] ; Anne Romstad [Danemark] ; Lisbeth Birk M Ller [Danemark] | Levodopa-responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections |
| 001E10 |
David R. Williams [Royaume-Uni] ; Ali Hadeed [Jordanie] ; Amir S. Najim Al-Din [Royaume-Uni] ; Abdel-Latif Wreikat [Jordanie] ; Andrew Lees (neurologue) [Royaume-Uni] | Kufor Rakeb disease : Autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia |
| 001E21 |
Pierre-Olivier Femagut [États-Unis] ; Imad Ghorayeb [France] ; Elsa Diguet [France] ; Francois Tison [France] | In vivo models of multiple system atrophy |
| 001E31 |
Evzen Ruzicka [République tchèque] ; Dusan Urgosik [République tchèque] ; Robert Jech [République tchèque] ; Jan Roth [République tchèque] ; Josef Vymazal [République tchèque] ; Petr Mecir [République tchèque] ; Vilibald Vladyka [République tchèque] | Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion |
| 001E40 |
Manuela Contin [Italie] ; Paolo Martinelli [Italie] ; Mirella Mochi [Italie] ; Roberto Riva [Italie] ; Fiorenzo Albani [Italie] ; Agostino Baruzzi [Italie] | Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease |
| 001E53 |
Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 |
| 001E63 |
William Bara-Jimenez [États-Unis] ; Francesco Bibbiani [États-Unis] ; Michael J. Morris [États-Unis] ; Tzvetelina Dimitrova [États-Unis] ; Abdullah Sherzai [États-Unis] ; Maral M. Mouradian [États-Unis] ; Thomas N. Chase [États-Unis] | Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease |
| 001E65 |
Paolo Lamberti [Italie] ; Stefano Zoccolella [Italie] ; Giovanni Iliceto [Italie] ; Elio Armenise [Italie] ; Angela Fraddosio [Italie] ; Michele De Mari [Italie] ; Paolo Livrea [Italie] | Effects of levodopa and COMT inhibitors on plasma Homocysteine in Parkinson's disease patients |
| 001E68 |
Christine Brefel-Courbon [France] ; Pierre Payoux [France] ; Claire Thalamas [France] ; Fabienne Ory [France] ; Isabelle Quelven [France] ; Francois Chollet [France] ; Jean Louis Montastruc [France] ; Olivier Rascol [France] | Effect of levodopa on pain threshold in Parkinson's disease : A clinical and positron emission tomography study |
| 001E69 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada] | Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys |
| 001F07 |
Serge Pinto [France] ; Michèle Gentil [France] ; Paul Krack [France] ; Paul Sauleau [France] ; Valérie Fraix [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] | Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech |
| 001F71 |
Katherine Grosset [Royaume-Uni] ; Donald Grosset [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Trial of subtherapeutic pergolide in de novo Parkinson's disease |
| 001F79 |
Matthew J. Hansard [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sharon C. Cheetham [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates |
| 001F96 |
Jon Infante [Espagne] ; José Berciano [Espagne] ; Victor Volpini [Espagne] ; Jordi Corral [Espagne] ; José Miguel Polo [Espagne] ; Julio Pascual [Espagne] ; Onofre Combarros [Espagne] | Spinocerebellar ataxia type 2 with levodopa-responsive Parkinsonism culminating in motor neuron disease |
| 002006 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study |
| 002009 |
Alastair Wilkins [Royaume-Uni] ; Jerry M. Brown [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] | SCA2 presenting as levodopa-responsive parkinsonism in a young patient from the United Kingdom: A case report |
| 002078 |
Susan Fox [Royaume-Uni] ; Montague Silverdale ; Mark Kellett ; Rhys Davies ; Malcolm Steiger [Royaume-Uni] ; Nicholas Fletcher [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie | Non-subtype-selective Opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease |
| 002091 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Mikko Kuoppamaki [Royaume-Uni, États-Unis] ; Warren Olanow [Finlande] ; Peter Jenner [Royaume-Uni] | Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naïve primates |
| 002098 |
Padraig E. O'Suilleabhain [États-Unis] ; Teodoro Bottiglieri [États-Unis] ; Richard B. Jr Dewey [États-Unis] ; Shailja Sharma [États-Unis] ; Ramon Diaz-Arrastia [États-Unis] | Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease |
| 002111 |
Neeraj Kumar [États-Unis] ; Jay A. Van Gerpen [États-Unis] ; James H. Bower [États-Unis] ; J. Eric Ahlskog [États-Unis] | Levodopa-dyskinesia incidence by age of Parkinson's disease onset |
| 002112 |
Svenja Happe [Allemagne] ; Tobias Tings [Allemagne] ; Kathrin Helmschmied [Allemagne] ; Karin Neubert [Allemagne] ; Wolfgang Wuttke [Allemagne] ; Walter Paulus [Allemagne] ; Claudia Trenkwalder [Allemagne] | Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease |
| 002113 |
C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio ; Fabrizio Stocchi | Levodopa in the treatment of Parkinson's disease: Current controversies |
| 002119 |
Andrew H. Evans [Royaume-Uni] ; Durval C. Costa [Portugal] ; Sveto Gacinovic [Royaume-Uni] ; Regina Katzenschlager [Royaume-Uni] ; John D. O'Sullivan [Australie] ; Simon Heales [Royaume-Uni] ; Phillip Lee [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings |
| 002215 |
J. Eric Ahlskog [États-Unis] | Challenging conventional wisdom : The etiologic role of dopamine oxidative stress in Parkinson's disease |
| 002254 |
Yoshiaki Furukawa [Canada] ; James J. Filiano [États-Unis] ; Stephen J. Kish [Canada] | Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations |
| 002318 |
Tomoyuki Uchiyama [Japon] ; Ryuji Sakakibara [Japon] ; Takamichi Hattori [Japon] ; Tomonori Yamanishi [Japon] | Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon |
| 002328 |
Haydeh Payami [États-Unis] ; John Nutt [États-Unis] ; Steven Gancher [États-Unis] ; Thomas Bird [États-Unis] ; Melissa Gonzales Mcneal [États-Unis] ; William K. Seltzer [États-Unis] ; Jennifer Hussey [États-Unis] ; Paul Lockhart [États-Unis] ; Katrina Gwinn-Hardy [États-Unis] ; Amanda A. Singleton [États-Unis] ; Andrew B. Singleton [États-Unis] ; John Hardy [États-Unis] ; Matthew Farrer [États-Unis] | SCA2 may present as levodopa-responsive parkinsonism |
| 002344 |
Yoshikuni Mizuno [Japon] ; Nobuo Yanagisawa [Japon] ; Sadako Kuno [Japon] ; Mitsutoshi Yamamoto [Japon] ; Kazuko Hasegawa [Japon] ; Hideki Origasa [Japon] ; Hisayuki Kowa [Japon] | Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease |
| 002387 |
Claudia Trenkwalder [Allemagne] ; Victor Collado Seidel [Allemagne] ; Jörg Kazenwadel [Suisse] ; Thomas C. Wetter [Allemagne] ; Wolfgang Oertel [Allemagne] ; Roland Selzer [Allemagne] ; Ralf Kohnen [Allemagne] | One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome? |
| 002391 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 002419 |
Jau-Shin Lou [États-Unis] ; Greg Kearns [États-Unis] ; Theodore Benice [États-Unis] ; Barry Oken [États-Unis] ; Gary Sexton [États-Unis] ; John Nutt [États-Unis] | Levodopa improves physical fatigue in Parkinson's disease: A double-blind, placebo-controlled, crossover study |
| 002450 |
Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease |
| 002465 |
Kathy Steece-Collier [États-Unis] ; Timothy J. Collier [États-Unis] ; Paul D. Danielson [États-Unis] ; Roger Kurlan [États-Unis] ; David M. Yurek [États-Unis] ; John R. Jr Sladek [États-Unis] | Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in Parkinsonian rats |
| 002467 |
Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study |
| 002469 |
Amy J. Bastian [États-Unis] ; Valerie E. Kelly [États-Unis] ; Joel S. Perlmutter [États-Unis] ; Jonathan W. Mink [États-Unis] | Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease |
| 002471 |
Gregorio Segovia [Royaume-Uni, Espagne] ; Francisco Mora [Espagne] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease |
| 002472 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson ; Matthew J. Hansard ; Eleni Maratos ; Peter Jenner | Effect of pulsatile administration of Levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure |
| 002484 |
Ronald B. Postuma [Canada, États-Unis] ; Yoshiaki Furukawa [Canada] ; Ekaterina Rogaeva [Canada] ; Peter H. St. George-Hyslop [Canada] ; Matt J. Farrer [Canada] ; Anthony E. Lang [Canada] | Dopa-responsive dystonia presenting with prominent isolated bilateral resting leg tremor: Evidence for a role of Parkin? |
| 002514 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
| 002518 |
Cathy Chuang [États-Unis] ; Anne Constantino [États-Unis] ; Casilda Balmaceda [États-Unis] ; David Eidelberg [États-Unis] ; Steven J. Frucht [États-Unis] | Chemotherapy-induced Parkinsonism responsive to levodopa: An underrecognized entity |
| 002519 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
| 002524 |
Antje M. Smala [Allemagne] ; E. Annika Spottke [Allemagne] ; Olaf Machat [Allemagne] ; Uwe Siebert [États-Unis] ; Dieter Meyer [Allemagne] ; Rudolf Köhne-Volland [Allemagne] ; Martin Reuther [Allemagne] ; Janeen Duchane [États-Unis] ; Wolfgang H. Oertel [Allemagne] ; Karin B. Berger [Allemagne] ; Richard C. Dodel [Allemagne] | Cabergoline versus levodopa monotherapy: A decision analysis |
| 002532 |
Noël L. W. Keijsers [Pays-Bas] ; Martin W. I. M. Horstink [Pays-Bas] ; Stan C. A. M. Gielen [Pays-Bas] | Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks |
| 002545 |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Paul Krack [France] ; Valérie Fraix [France] ; Nadège Van Blercom [France] ; JING XIE [France] ; Elena Moro [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] | Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease |
| 002556 |
Ergun Y. Uc [États-Unis] ; Gerald A. Dienel [États-Unis] ; Nancy F. Cruz [États-Unis] ; Sami I. Harik [États-Unis] | β-Adrenergics enhance brain extraction of levodopa |
| 002565 |
Padraic J. Grattan-Smith [Australie] ; Ron A. Wevers [Pays-Bas] ; Gerry C. Steenbergen-Spanjers [Pays-Bas] ; Victor S. C. Fung [Australie] ; John Earl [Australie] ; Bridget Wilcken [Australie] | Tyrosine hydroxylase deficiency: Clinical manifestations of catecholamine insufficiency in infancy |
| 002585 |
Louis C. Tan [États-Unis] ; Peter H. Protell [États-Unis] ; J. William Langston [États-Unis] ; Daniel M. Togasaki [États-Unis] | The Hyperkinetic Abnormal Movements Scale: A tool for measuring levodopa-induced Abnormal Movements in squirrel monkeys |
| 002601 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni] | Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
| 002626 |
Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation |
| 002631 |
Robert A. Hauser [États-Unis] ; Nicholas H. G. Holford [Nouvelle-Zélande] | Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's Disease |
| 002636 |
Sam Birdi [Canada] ; Ali H. Rajput [Canada] ; Mark Fenton [Canada] ; Jeffery R. Donat [Canada] ; Bohdan Rozdilsky [Canada] ; Christopher Robinson [Canada] ; Rob Macaulay [Canada] ; David George [Canada] | Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases |
| 002671 |
Ruth Djaldetti [Israël] ; Rivkah Inzelberg [Israël] ; Nir Giladi [Israël] ; Amos D. Korczyn [Israël] ; Yehudit Peretz-Aharon [Israël] ; Martin J. Rahey [Israël] ; Yuval Herishano [Israël] ; Silvia Honigman [Israël] ; Sami Badarny [Israël] ; Eldad Melamed [Israël] | Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease |
| 002686 |
Craig D. Mccoll [Australie] ; Katrina A. Reardon [Australie] ; Mark Shiff [Australie] ; Peter A. Kempster [Australie] | Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease |
| 002705 |
| Levodopa |
| 002706 |
Miriam Velez [Pérou] ; Carlos Cosentino [Pérou] ; Luis Torres [Pérou] | Levodopa-responsive rubral (Holmes') tremor |
| 002707 |
Gurutz Linazasoro [Espagne] ; Nadege Van Blercom [Espagne] ; Asier Lasa [Espagne] | Levodopa-induced ocular dyskinesias in Parkinson's disease |
| 002708 |
Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque] | Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up |
| 002709 |
Jong-Min Kim [Corée du Sud] ; KI HYEONG LEE [Corée du Sud] ; Yoon-La Choi [Corée du Sud] ; GI YEONG CHOE [Corée du Sud] ; Beom S. Jeon [Corée du Sud] | Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy |
| 002710 |
Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France] | Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in Parkinsonian rats |
| 002727 |
Valerie E. Kelly [États-Unis] ; Allie S. Hyngstrom [États-Unis] ; Melissa M. Rundle [États-Unis] ; Amy J. Bastian [États-Unis] | Interaction of levodopa and cues on voluntary reaching in Parkinson's disease |
| 002728 |
Luc J. P. Defebvre [France] ; Pierre Krystkowiak [France] ; Jean-Louis Blatt [France] ; Alain Duhamel [France] ; Jean-Louis Bourriez [France] ; Myriame Perina [France] ; Serge Blond [France] ; Jean-Daniel Guieu [France] ; Alain Destée [France] | Influence of pallidal stimulation and levodopa on gait and preparatory postural adjustments in Parkinson's disease |
| 002771 |
Ashfaq A. Sharif [États-Unis] | Entacapone in restless legs syndrome |
| 002792 |
Oleh Hornykiewicz [Autriche] | Dopamine miracle: From brain homogenate to dopamine replacement |
| 002793 |
Monica J. Ling [Australie] ; Arun Aggarwal [Australie] ; John G. L. Morris [Australie] | Dopa-responsive parkinsonism secondary to right temporal lobe haemorrhage |
| 002794 |
Chin-Song Lu [Taïwan] ; Yah-Huei Wu Chou [Taïwan] ; Tzu-Chen Yen [Taïwan] ; Chon-Haw Tsai [Taïwan] ; Rou-Shayn Chen [Taïwan] ; Hsiu-Chen Chang [Taïwan] | Dopa-responsive parkinsonism phenotype of spinocerebellar ataxia type 2 |
| 002797 |
J. E. Rice [Australie] ; R. Antic [Australie] ; Philip D. Thompson [Australie] | Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease |
| 002807 |
Diego Garcia-Borreguero [Espagne] ; Ana B. Caminero [Espagne] ; Yolanda De La Llave [Espagne] ; Oscar Larrosa [Espagne] ; Soledad Barrio [Espagne] ; Juan J. Granizo [Espagne] ; Juan A. Pareja [Espagne] | Decreased phasic EMG activity during Rapid eye movement sleep in treatment-naïve Parkinson's disease: Effects of treatment with levodopa and progression of illness |
| 002826 |
Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche] | Clinical-pathological study of levodopa complications |
| 002847 |
Francesc Valldeoriola [Espagne] ; Manuela Pilleri [Espagne] ; Eduardo Tolosa [Espagne] ; José L. Molinuevo [Espagne] ; Jordi Rumia [Espagne] ; Enric Ferrer [Espagne] | Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: Long-term follow-up of patients |
| 002851 |
Mikko Kuoppam Ki [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Michael Jackson [Royaume-Uni] ; Lance Smith [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa |
| 002867 |
Marcelo Merello [Argentine] ; Maria I. Nouzeilles [Argentine] ; Gabriel Piran Arce [Argentine] ; Ramon Leiguarda [Argentine] | Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis |
| 002902 |
Elan D. Louis [États-Unis] ; Linda Winfield [États-Unis] ; Stanley Fahn [États-Unis] ; Blair Ford [États-Unis] | Speech dysfluency exacerbated by levodopa in Parkinson's disease |
| 002919 |
William Koller [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie] | Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations |
| 002927 |
Anette Schrag [Royaume-Uni] ; Michael Trimble [Royaume-Uni] | Poetic talent unmasked by treatment of Parkinson's disease |
| 002946 |
J. Hoenicka [Espagne] ; L. Vidal [Espagne] ; M. Godoy [Espagne] ; J. J. Ochoa [Espagne] ; J. Garcia De Yebenes [Espagne] | New nonsense mutation in the GTP-cyclohydrolase I gene in L-DOPA responsive dystonia-parkinsonism |
| 002949 |
P. H. Gordon [États-Unis] ; S. J. Frucht [États-Unis] | Neuroleptic malignant syndrome in advanced Parkinson's disease |
| 002952 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan |
| 002964 |
Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France] | Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease |
| 002971 |
Birgit Högl [Autriche] ; Md. Klaus Seppi [Autriche] ; Elisabeth Brandauer [Autriche] ; Gregor Wenning [Autriche] ; Werner Poewe [Autriche] | Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy: Placebo-controlled, polysomnographic case report |
| 002973 |
Paolo Del Dotto [Italie] ; Nicola Pavese [Italie] ; Gianna Gambaccini [Italie] ; Silvia Bernardini [Italie] ; Leonard Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Ubaldo Bonuccelli [Italie] | Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study |
| 002997 |
J. Eric Ahlskog [États-Unis] ; Manfred D. Muenter [États-Unis] | Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature |
| 002A28 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 002A36 |
Krishna P. Datla [Royaume-Uni] ; Stavia B. Blunt [Royaume-Uni] ; David T. Dexter [Royaume-Uni] | Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostriatal lesions |
| 002A60 |
Eleni C. Maratos [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus) |
| 002A67 |
J. I. Hoff [Pays-Bas] ; A. A. V. D. Plas [Pays-Bas] ; E. A. H. Wagemans [Pays-Bas] ; J. J. Van Hilten [Pays-Bas] | Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease |
| 002A92 |
R. A. Hauser [États-Unis] ; W. C. Koller [États-Unis] ; J. P. Hubble [États-Unis] ; T. Malapira [États-Unis] ; K. Busenbark [États-Unis] ; C. W. Olanow [États-Unis] | Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease |
| 002A96 |
Hasmet A. Hanagasi [Turquie] ; Gülüstü Kaptanoglu [Turquie] ; Hüseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa |
| 002B03 |
C. Ramaker [Pays-Bas] ; W. J. T. Van De Beek [Pays-Bas] ; M. J. J. Finken [Pays-Bas] ; B. J. J. Van Hilten [Pays-Bas] | The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications : A systematic review |
| 002B05 |
I. Reuter [Royaume-Uni] ; S. Harder [Allemagne] ; M. Engelhardt [Allemagne] ; H. Baas [Allemagne] | The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa |
| 002B23 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
| 002B25 |
Kevin J. Black [États-Unis] ; Jonathan W. Mink [États-Unis] | Response to levodopa challenge in Tourette syndrome |
| 002B48 |
José Antonio Molina [Espagne] ; Maria José Sainz-Artiga [Espagne] ; Talicia Fraile [Espagne] ; Félix Javier Jimenez-Jimenez [Espagne] ; Clara Villanueva [Espagne] ; Miguel Orti-Pareja [Espagne] ; Félix Bermeio-P [Espagne] | Pathologic gambling in Parkinson's disease : A behavioral manifestation of pharmacologic treatment? |
| 002B76 |
S. Frucht [États-Unis] ; S. Fahn [États-Unis] ; S. Chin [États-Unis] ; V. Dhawan [États-Unis] ; D. Eidelberg [États-Unis] | Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration |
| 002B83 |
Doron Merims [Israël] ; Ronit Galili-Mosberg [Israël] ; Eldad Melamed [Israël] | Is there addiction to levodopa in patients with Parkinson's disease? |
| 002B91 |
T. E. Kimber [Australie] ; P. D. Thompson [Australie] | Increased blink rate in advanced Parkinson's disease : A form of 'off'-period dystonia? |
| 002B94 |
A. J. Manson [Royaume-Uni] ; E. Iakovidou [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease |
| 002C10 |
Sarah A. Treseder [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Endogenous dopaminergic tone and dopamine agonist action |
| 002C21 |
C. G. Goetz [États-Unis] ; G. T. Stebbins [États-Unis] ; L. M. Blasucci [États-Unis] | Differential progression of motor impairment in levodopa-treated Parkinson's Disease |
| 002C23 |
N. L. W. Keijsers [Pays-Bas] ; M. W. I. M. Horstink [Pays-Bas] ; J. J. Van Hilten [Pays-Bas] ; J. I. Hoff [Pays-Bas] ; C. C. A. M. Gielen [Pays-Bas] | Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks |
| 002C37 |
J. Kulisevsky [Espagne] ; C. Garcia-Sanchez [Espagne] ; M. L. Berthier [Espagne] ; M. Barbanoj [Espagne] ; B. Pascual-Sedano [Espagne] ; A. Gironell [Espagne] ; A. Estevez-Gonzalez [Espagne] | Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease : A two-year follow-up study of previously untreated patients |
| 002C45 |
H. Apaydin [Turquie] ; S. Ertan [Turquie] ; S. Özekmekci [Turquie] | Broad bean (Vicia faba) : A natural source of L-dopa : Prolongs "on" periods in patients with Parkinson's disease who have "on-off" fluctuations |
| 002C52 |
E. Luginger [Autriche] ; G. K. Wenning [Autriche] ; S. Bosch [Autriche] ; Werner Poewe [Autriche] | Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's Disease |
| 002C53 |
K. Ray Chaudhuri [Royaume-Uni] ; M. T. M. Hu [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] | Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK |
| 002C54 |
J. H. Friedman [États-Unis] ; S. A. Factor | Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease |
| 002C84 |
| Dyskinesias |
| 002D03 |
M. Vidailhet [France] ; A. M. Bonnet [France] ; R. Marconi [France] ; F. Durif [France] ; Yves Agid [France] | The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease |
| 002D04 |
W. J. Weiner [États-Unis] | The initial treatment of Parkinson's disease should begin with levodopa |
| 002D09 |
S. Spieker [Allemagne] ; P.-A. Löschmann [Allemagne] ; T. Klockgether [Allemagne] | The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations |
| 002D22 |
A. Churchyard [Royaume-Uni] ; C. J. Mathias [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Selegiline-induced postural hypotension in Parkinson's disease : A longitudinal study on the effects of drug withdrawal |
| 002D25 |
D. Mathen [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; K. P. Bhatia [Royaume-Uni] | SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia |
| 002D35 |
J. M. Brotchie [Royaume-Uni] ; S. H. Fox [Royaume-Uni] | Quantitative assessment of dyskinesias in subhuman primates |
| 002D37 |
H. H. Fernandez [États-Unis] ; J. H. Friedman [États-Unis] | Punding on L-dopa |
| 002D54 |
P. J. Bedard [Canada] ; P. J. Blanchet [Canada] ; D. Levesque [Canada] ; J.-J. Soghomonian [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; F. Calon [Canada] ; P. Falardeau [Canada] ; B. Gomez-Mancilla [Canada] ; J.-P. Doucet [Canada] ; G. S. Robertson [Canada] ; T. Dipaolo [Canada] | Pathophysiology of L-Dopa-induced dyskinesias |
| 002D74 |
J. Kimber [Royaume-Uni] ; L. Watson ; C. J. Mathias | Neuroendocrine responses to levodopa in multiple system atrophy (MSA) |
| 002D93 |
N. Giladi [Israël] ; E. Melamed [Israël] | Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism |
| 002D96 |
Olivier Rascol [France] | L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach |
| 002D97 |
R. K. B. Pearce [Royaume-Uni] | L-dopa and dyskinesias in normal monkeys |
| 002E24 |
| Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients |
| 002E25 |
R. B. Innis [États-Unis] ; K. L. Marek [États-Unis] ; K. Sheff [États-Unis] ; S. Zoghbi [États-Unis] ; J. Castronuovo [États-Unis] ; A. Feigin [États-Unis] ; J. P. Seibyl [États-Unis] | Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT |
| 002E33 |
Y. Furukawa [Canada] ; S. J. Kish [Canada] | Dopa-responsive dystonia : Recent advances and remaining issues to be addressed |
| 002E67 |
E. Moro [Italie] ; A. Albanese [Italie, Suisse] | Apomorphine and levodopa challenge in patients with a focal midbrain lesion |
| 002F15 |
N. Syed [États-Unis] ; J. Murphy [États-Unis] ; T. Jr Zimmerman [États-Unis] ; M. H. Mark [États-Unis] ; J. I. Sage [États-Unis] | Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease |
| 002F21 |
P. Van Den Munckhof [États-Unis] ; F. A. Lenz [États-Unis] ; T. N. Chase [États-Unis] ; L. V. Metman [États-Unis] | Square-wave action dystonia in Parkinson's disease |
| 002F26 |
Olivier Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
| 002F41 |
P. Hagell [Suède] ; P. Odin [Allemagne] ; E. Vinge [Suède] | Pregnancy in Parkinson's disease : A review of the literature and a case report |
| 002F51 |
P. G. Wasielewski [États-Unis] ; J. M. Burns [États-Unis] ; W. C. Koller [États-Unis] | Pharmacologic treatment of tremor |
| 002F57 |
E. J. Skalabrin [États-Unis] ; E. R. Jr Laws [États-Unis] ; J. P. Jr Bennett [États-Unis] | Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease |
| 002F86 |
N. R. Hughes [Royaume-Uni] ; A. T. Mcknight [Royaume-Uni] ; G. N. Woodruff [Royaume-Uni] ; M. P. Hill [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism |
| 002F89 |
P. Krack [France] ; Pierre Pollak [France] ; P. Limousin [France] ; D. Hoffmann [France] ; A. Benazzouz [France] ; Alim-Louis Benabid [France] | Inhibition of levodopa effects by internal pallidal stimulation |
| 003011 |
J. D. O'Sullivan [Australie] ; C. M. Said [Australie] ; L. C. Dillon [Australie] ; M. Hoffman [Australie] ; A. J. Hughes [Australie] | Gait analysis in patients with Parkinson's disease and motor fluctuations : Influence of levodopa and comparison with other measures of motor function |
| 003027 |
J. S. Schneider [États-Unis] ; A. Pope-Coleman [États-Unis] ; M. Van Velson [États-Unis] ; F. Menzaghi [États-Unis] ; G. K. Lloyd [États-Unis] | Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys |
| 003038 |
A. P. Payne [Royaume-Uni] ; R. G. Sutcliffe [Royaume-Uni] ; J. M. Campbell [Royaume-Uni] ; G. Favor [Royaume-Uni] ; D. Russell [Royaume-Uni] ; N. K. Bennett [Royaume-Uni] ; D. J. Clarke [Royaume-Uni] ; R. Branton [Royaume-Uni] ; R. W. Davies [Royaume-Uni] ; E. Simpson [Royaume-Uni] ; C. Tsang [Royaume-Uni] ; R. H. Baxendale [Royaume-Uni] | Disordered locomotion in the AS/AGU mutant rat and the effects of L-dopa or fetal midbrain grafts |
| 003044 |
R. K. B. Pearce [Royaume-Uni] ; T. Banerji ; P. Jenner ; C. D. Marsden | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset |
| 003052 |
P. A. Lewitt [États-Unis] | Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease |
| 003059 |
H. H. Fernandez [États-Unis] ; R. Durso [États-Unis] | Clozapine for dopaminergic-induced paraphilias in Parkinson's disease |
| 003075 |
S. Dethy [Belgique] ; N. Van Blercom [Belgique] ; P. Damhaut [Belgique] ; D. Wikler [Belgique] ; J. Hildebrand [Belgique] ; S. Goldman [Belgique] | Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism |
| 003085 |
P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; T. N. Chase [États-Unis] | Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys |
| 003088 |
J. M. Brotchie [Royaume-Uni] | Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease |
| 003094 |
L. V. Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; P. Van Den Munckhof [États-Unis] ; P. Del Dotto [États-Unis] ; R. Natte [États-Unis] ; T. N. Chase [États-Unis] | A trial of dextromethorphan in Parkinsonian patients with motor response complications |
| 003102 |
J. Schwarz [Allemagne] ; K. Tatsch [Allemagne] ; T. Gasser [Allemagne] ; G. Arnold [Allemagne] ; O. Pogarell [Allemagne] ; G. Künig [Allemagne] ; W. H. Oertel [Allemagne] | 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism |
| 003118 |
E. Dupont [Danemark] ; J.-M. Burgunder [Suisse] ; L. J. Findley [Royaume-Uni] ; J.-E. Olsson [Suède] ; E. Dorflinger [États-Unis] | Tolcapone added to levodopa in stable parkinsonian patients : A double-blind placebo-controlled study |
| 003125 |
P. Lewitt [États-Unis] ; D. Oakes [États-Unis] ; L. Cui [États-Unis] | The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α-tocopherol |
| 003127 |
J. P. Larsen [Norvège] ; J. Boas [Danemark] | The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability : An interim analysis of a Norwegian-Danish 5-year study |
| 003128 |
L. Rioux [États-Unis] ; P. A. Frohna [États-Unis] ; J. N. Joyce [États-Unis] ; J. S. Schneider [États-Unis] | The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys |
| 003129 |
F. Lobbezoo [Canada] ; G. J. Lavigne [Canada] ; R. Tanguay [Canada] ; J. Y. Montplaisir [Canada] | The effect of the catecholamine precursor L-dopa on sleep bruxism : A controlled clinical trial |
| 003146 |
A. Burleigh-Jacobs [États-Unis] ; F. B. Horak [États-Unis] ; J. G. Nutt [États-Unis] ; J. A. Obeso [Espagne] | Step initiation in Parkinson's disease : Influence of levodopa and external sensory triggers |
| 003152 |
M. Zappia [Italie] ; R. Montesanti [Italie] ; R. Colao [Italie] ; D. Branca [Italie] ; G. Nicoletti [Italie] ; U. Aguglia [Italie] ; A. Quattrone [Italie] | Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease |
| 003194 |
J. G. Nutt [États-Unis] ; J. H. Carter [États-Unis] ; E. S. Lea [États-Unis] ; W. R. Woodward [États-Unis] | Motor fluctuations during continuous Levodopa infusions in patients with Parkinson's disease |
| 003196 |
M. Gu [Royaume-Uni] ; M. T. Gash [Royaume-Uni] ; J. M. Cooper [Royaume-Uni] ; G. K. Wenning [Royaume-Uni] ; S. E. Daniel [Royaume-Uni] ; N. P. Quinn [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; A. H. V. Schapira [Royaume-Uni] | Mitochondrial respiratory chain function in multiple system atrophy |
| 003205 |
I. Ziv [Israël] ; R. Zilkha-Falb [Israël] ; D. Offen [Israël] ; A. Shirvan [Israël] ; A. Barzilai [Israël] ; E. Melamed [Israël] | Levodopa induces apoptosis in cultured neuronal cells : A possible accelerator of nigrostriatal degeneration in Parkinson's disease? |
| 003209 |
A. H. Rajput [Canada] ; M. E. Fenton [Canada] ; S. Birdi [Canada] ; R. Macaulay [Canada] | Is levodopa toxic to human substantia nigra? |
| 003218 |
K. Ikeda [Japon] ; M. Kinoshita [Japon] ; K. Aoki [Japon] ; A. Tomatsuri [Japon] | Hydrocephalic parkinsonism due to Paget's disease of bone : Dramatic improvement following ventriculoperitoneal shunt and temporary levodopa/carbidopa therapy |
| 003232 |
L. A. Smith [Royaume-Uni] ; A. Gordin [Finlande] ; P. Jenner [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets |
| 003238 |
A. Rajput [États-Unis] ; A. Kishore [Canada] ; B. Snow [Canada] ; C. F. Bolton [Canada] ; A. H. Rajput [Canada] | Dopa-responsive, nonprogressive, juvenile parkinsonism : Report of a case |
| 003254 |
R. Pahwa [États-Unis] ; K. Lyons [États-Unis] ; D. Mcguire [États-Unis] ; P. Silverstein [États-Unis] ; F. Zwiebel [États-Unis] ; M. Robischon [États-Unis] ; W. C. Koller [États-Unis] | Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease : Pharmacokinetic and quality-of-life measures |
| 003261 |
G. Gomez Arevalo [Argentine] ; R. Jorge [Argentine] ; S. Garcia [Argentine] ; O. Scipioni [Argentine] ; O. Gershanik [Argentine] | Clinical and pharmacological differences in early- versus late-onset Parkinson's disease |
| 003328 |
A. Tan [États-Unis] ; M. Salgado [États-Unis] ; S. Fahn [États-Unis] | Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa |
| 003335 |
F. Picard [France] ; A. De Saint-Martin [France] ; E. Salmon [Belgique] ; E. Hirsch [France] ; C. Marescaux [France] | Postencephalitic stereotyped involuntary movements responsive to L-Dopa |
| 003336 |
R. Pahwa [États-Unis] ; J. Marjama [États-Unis] ; D. Mcguire [États-Unis] ; K. Lyons [États-Unis] ; F. Zwiebel ; P. Silverstein ; R. Ward ; W. C. Koller [États-Unis] | Pharmacokinetic comparison of Sinemet and atamet (generic carbidopa/levodopa) : A single-dose study |
| 003352 |
E. J. Pappert [États-Unis] ; C. Buhrfiend ; J. W. Lipton ; P. M. Carvey ; G. T. Stebbins ; C. G. Goetz | Levedopa stability in solution : time course, environmental effects, and practical recommendations for clinical use |
| 003398 |
P. D. Clouston [Australie] ; C. L. Lim [Australie] ; V. Fung [Australie] ; C. Yiannikas [Australie] ; J. G. L. Morris [Australie] | Brainstem myoclonus in a patient with non-dopa-responsive parkinsonism |
| 003407 |
D.-E. Shan [Taïwan] ; S.-Y. Kwan [Taïwan] ; H.-H. Ho [Taïwan] ; M.-S. Su [Taïwan] | Belly dystonia induced by levodopa and biperiden in a case of suspected multiple-system atrophy |
| 003416 |
P. J. Blanchet [États-Unis] ; L. V. Metman [États-Unis] ; M. M. Mouradian [États-Unis] ; T. N. Chase [États-Unis] | Acute pharmacologic blockade of dyskinesias in Parkinson's disease |
| 003435 |
W. Diaz Neira [Espagne] ; V. Sanchez ; M. A. Mena ; J. G. De Yebenes | The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease |
| 003455 |
M. Di Capua [Italie] ; E. Bertini | Remission in dihydroxyphenylalanine-responsive dystonia |
| 003475 |
R. A. Maricle [États-Unis] ; J. G. Nutt ; J. H. Carter | Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion : preliminary findings |
| 003477 |
G. Fabbrini [Italie] ; F. Baronti ; S. Ruggieri ; G. L. Lenzi | Meningioma-induced loss of antiparkinsonian response to levodopa |
| 003503 |
R. Djaldetti [Israël] ; M. Koren ; ILAN ZIV ; A. Achiron ; ELDAD MELAMED | Effect of cisapride on response fluctuations in Parkinson's disease |
| 003506 |
C. E. Clarke [Royaume-Uni] | Does levodopa therapy delay death in Parkinson's disease ? A review of the evidence |
| 003519 |
M. H. Mark [États-Unis] ; J. I. Sage ; A. S. Walters ; R. C. Duvoisin ; D. C. Miller | Binswanger's disease presenting as levodopa-responsive parkinsonism : clinicopathologic study of three cases |
| 003539 |
G. K. Wenning [Royaume-Uni] ; M. T. O'Connell ; P. N. Patsalos ; N. P. Quinn | A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease |
| 003540 |
A. M. Bonnet [France] ; I. Serre [France] ; R. Marconi [France] ; Yves Agid [France] ; B. Dubois [France] | A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists : application to pergolide and bromocriptine |
| 003602 |
R. Marconi [France] ; D. Lefebvre-Caparros ; A.-M. Bonnet [France] ; M. Vidailhet [France] ; B. Dubois [France] ; Yves Agid [France] | Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology |
| 003614 |
L. Verhagen Metman [États-Unis] ; J. Hoff ; M. M. Mouradian ; T. N. Chase | Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa |
| 003648 |
C. W. Olanow [États-Unis] ; S. Fahn ; M. Muenter ; H. Klawans ; H. Hurtig ; M. Stern ; I. Shoulson ; R. Kurlan ; J. D. Grimes ; Joseph Jankovic [États-Unis] ; M. Hoehn ; C. H. Markham ; R. Duvoisin ; O. Reinmuth ; H. A. Leonard ; E. Ahlskog ; R. Feldman ; L. Hershey ; M. D. Yahr | A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet® in Parkinson's disease |
| 003871 |
F. Dagani [Italie] ; R. Ferrari ; J. I. Anderson ; T. N. Chase | L-Dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria |
| 003997 |
P. A. Kempster ; Andrew Lees (neurologue) [Royaume-Uni] ; P. Crichton ; J. P. Fkankel ; P. Shorvon | Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine |
| 003A78 |
J. L. Montastruc ; P. Celsis ; A. Agniel ; J. F. Demonet ; B. Doyon ; M. Puel ; J. P. Marc-Vergnes ; A. Rascol | Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease: lack of correlation with clinical or neuropsychological improvements |
